Screener
BridgeBio Pharma BBIO Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (951) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 204,386,699 shares issued and 195,707,702 shares outstanding as of March 31, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 204 | 202 |
| Treasury stock, at cost; 8,678,997 shares as of March 31, 2026; 7,597,172 shares as of December 31, 2025 | (405,776) | (323,276) |
| Additional paid-in capital | 2,112,454 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (8) | 12 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's preferred stock par value per share?
- BridgeBio Pharma (BBIO) reported preferred stock par value per share of $0.00 in Q1 2026.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about BridgeBio Pharma's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude